The Business Of Biotech Podcast
-
A Rescue Model For Shelved Drug Candidates With Annette Bakker, Ph.D. And Andrew Lo, Ph.D.
7/30/2026
On this week's episode of the Business of Biotech, Annette Bakker, Ph.D., CEO at the Children's Tumor Foundation, and Andrew Lo, Ph.D., Finance Professor at MIT's Sloan School of Management and Director of the Laboratory for Financial Engineering, talk about the methods and economics for turning abandoned drug candidates into new therapies for patients.
-
Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D.
7/23/2026
On this week's episode of the Business of Biotech, Aris Baras, M.D., SVP, Head of Regeneron Genetics Center (RGC) and Co-Head of Regeneron Genetic Medicines, talks about using large-scale human genetics to find better drug targets based on "superhuman" variants.
-
Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
7/15/2026
On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in dementia with Lewy bodies (DLB) and commercial planning for an anticipated launch.
-
BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
7/9/2026
On the Business of Biotech this week, industry veteran Dr. Jeremy Levin, Founder, Chairman, and former CEO at Ovid Therapeutics, sits down alongside the 2026 BIO Convention to talk about why public distrust and politicized institutions are putting the scientific enterprise at risk.
-
BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
7/2/2026
This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work.
-
Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.
6/19/2026
On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale.
-
Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
6/19/2026
On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma.
-
Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
6/12/2026
On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks about why biotech drug launches so often miss expectations, and how to build an integrated commercialization plan that holds up with physicians, patients, and payers.
-
The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry
6/5/2026
On this week's episode of the Business of Biotech, Tyler Menichiello, chief editor at Bioprocess Online, host of the Better Biopharma podcast, and my Life Science Connect (LSC) colleague, convenes the broader LSC editorial team once again for a midyear discussion on what's happening now in the life sciences industry, and what's to come in the second half of the year.
-
Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.
5/28/2026
On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen.